Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...

The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...

The addition of the ABL Rockville team and facility aligns more than three decades of development and manufacturing experience with additional virus modalities and GMP capacity for adeno-associated ...

As a combined company, we have an expanded pipeline that includes seven assets from our adeno-associated virus (AAV)-based gene therapy portfolio, each of them being developed for a specific IRD, as ...

Ascend’s fill/finish capacity in the US will also be expanded. “We founded Ascend with a vision to quilt together the best operators and technologies within the advanced manufacturing field. The ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...

Fractyl Health's Rejuva® platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered ...

When looking at Neurogene’s stock performance year-to-date, it’s hard to ignore the impressive +269.09% increase. However, this recent downturn suggests that the market is responding to something ...